Skip to main content
SpringerLink
Log in

Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson’s disease

  • Biochemistry, Biophysics and Molecular Biology
  • Published:
Doklady Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The goal of this study was to investigate the changes in the concentrations of blood plasma catecholamines as possible biomarkers of Parkinson’s disease (PD) in the mouse experimental model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). A significant decrease was detected in the levels of dopamine and L-DOPA in the PD preclinical stage model as a result of the catecholamines systemic metabolism disfunction. In the PD early clinical stage models, the level of L-DOPA and dihydroxyphenylacetic acid decreased, which is consistent with the results of blood tests in untreated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ugryumov, M.V., in Neirodegenerativnye zabolevaniya: ot genoma do tselostnogo organizma (Neurodegenerative Diseases: From Genome to Whole Body), Moscow: Nauchnyi Mir, 2014, vol. 1, pp. 22–44.

    Google Scholar 

  2. Goldstein, D.S., Comp. Physiol., 2014, vol. 4, pp. 805–826.

    Article  Google Scholar 

  3. Comi, C., Magistrelli, L., Oggioni, G.D., Carecchio, M., Fleetwood, T., Cantello, R., Mancini, F., and Antonini, A., Parkinsonism Relat. Disord., 2014, vol. 20, pp. 1329–1334.

    Article  CAS  PubMed  Google Scholar 

  4. Kolacheva, A.A., Kozina, E.A., Khakimova, G.R., Kucheryanu, V.G., Kudrin, V.S., Nigmatullina, R.R., Bazyan, A.S., Grigor’yan, G.A., and Ugryumov, M.V., in Neirodegenerativnye zabolevaniya: ot genoma do tselostnogo organizma (Neurodegenerative Diseases: From Genome to Whole Body), Moscow: Nauchnyi Mir, 2014, vol. 1, pp. 356–422.

    Google Scholar 

  5. Ugrumov, M.V., Khaindrava, V.G., Kozina, E.A., Kucheryanu, V.G., Bocharov, E.V., Kryzhanovsky, G.N., Kudrin, V.S., Narkevich, V.B., Klodt, P.M., Rayevsky, K.S., and Pronina, T.S., Neuroscience, 2011, vol. 181, pp. 175–188.

    Article  CAS  PubMed  Google Scholar 

  6. Jackson-Lewis, V. and Przedborski, S., Nat. Prot., 2007, vol. 2, pp. 141–151.

    Article  CAS  Google Scholar 

  7. Lucot, J.B., Jackson, N., Bernatova, I., and Morris, M., J. Pharmacol. and Toxicol. Methods, 2005, vol. 52, pp. 274–277.

    Article  CAS  Google Scholar 

  8. Goldstein, D.S., Eisenhofer, G., and Kopin, I.J., J. Pharmacol. Exp. Ther., 2003, vol. 305, pp. 800–811.

    Article  CAS  PubMed  Google Scholar 

  9. Stoddard, S.L., Merkel, G.J., Cook, J.A., Zinsmeister, A.R., and Carmichael, S.W., Microsci. Res. Tech., 1994, vol. 29, pp. 151–154.

    Article  CAS  Google Scholar 

  10. Chritton, S.L., Chinnow, S.L., Grabau, C., Dousa, M.K., Lucas, D., Roddy, D., Yaksh, T.L., and Tyce, G.M., J. Neurochem., 1997, vol. 69, pp. 2413–2420.

    Article  CAS  PubMed  Google Scholar 

  11. Zhao, C., Ling, Z., Newman, M.B., Bhatia, A., and Carvey, P.M., Neurobiol. Dis., 2007, vol. 26, pp. 36–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Ugrumov, M.V., Adv. Pharmacol., 2013, vol. 68, pp. 37–91.

    Article  CAS  PubMed  Google Scholar 

  13. Eldrup, E., Dan. Med. Bull., 2004, vol. 51, pp. 34–62.

    CAS  PubMed  Google Scholar 

  14. Nigmatullina, R.R., Zalyalova, Z.A., Kudrin, V.S., Pronina, T.S., Georgieva, S.G., Vorob’va, N.E., Soshnikova, N.V., Krasnov, A.N., Kuz’mina, O.I., and Ugryumov, M.V., in Neirodegenerativnye zabolevaniya: ot genoma do tselostnogo organizma (Neurodegenerative Diseases: From Genome to Whole Body), Moscow: Nauchnyi Mir, 2014, vol. 1, pp. 203–422.

    Google Scholar 

  15. Checkoway, H., Costa, L.G., Woods, J.S., Castoldi, A.F., Lund, B.O., and Swanson, P.D., J. Neural. Trans., 1992, vol. 4, pp. 283–290.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Koltzov Institute of Developmental Biology, Russian Academy of Sciences, ul. Vavilova 26, Moscow, 119334, Russia

    A. R. Kim & M. V. Ugryumov

Authors
  1. A. R. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. V. Ugryumov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. R. Kim.

Additional information

Original Russian Text © A.R. Kim, M.V. Ugryumov, 2015, published in Doklady Akademii Nauk, 2015, Vol. 464, No. 4, pp. 494–497.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, A.R., Ugryumov, M.V. Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson’s disease. Dokl Biochem Biophys 464, 308–311 (2015). https://doi.org/10.1134/S1607672915050105

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1607672915050105

Keywords

Search

Navigation